Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009437/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to acquire additional data on safety, tolerability and
immunogenicity of HyQvia in pediatric (age two to <18 years) patients with Primary
Immunodeficiency Diseases (PIDD)
提供机构：
Vivli
创建时间：
2023-11-20
